Hillstar Bio raises $67M for immunology drugs

The flurry of immunology biotech launches continues. Boston-based Hillstar Bio on Tuesday became the latest immunology startup launch, unveiling a $67 million Series A round funded by Droia Ventures, Frazier Life Sciences, Novo Holdings and ...

Related Posts

Bhattacharya is confirmed by Senate as NIH chief

Mar 25, 2025  0

Ahead of FDA decision, Alnylam faces the big question: ...

Mar 19, 2025  0

Labs fear future funding cuts with Trump administration...

Feb 13, 2025  0

Comments

Name

Email

Comment

Post Comment